Predicting Pediatric Age-Matched Weight and Body Mass Index

被引:18
作者
Sy, Sherwin K. B. [1 ]
Asin-Prieto, Eduardo [1 ]
Derendorf, Hartmut [1 ]
Samara, Emil [2 ]
机构
[1] Univ Florida, Dept Pharmaceut, Coll Pharm, Gainesville, FL 32610 USA
[2] PharmaPolaris Int, El Macero, CA USA
来源
AAPS JOURNAL | 2014年 / 16卷 / 06期
关键词
Age; Allometry; BMI; Pediatric; Weight; DRUG CLEARANCE; CHILDREN; PHARMACOKINETICS; GROWTH;
D O I
10.1208/s12248-014-9657-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The empirical scaling from adult to pediatric using allometric size adjustments based on body weight continued to be the mainstream method for pediatric dose selection. Due to the flexibility of a polynomial function to conform to the data trend, an empirical function for simulating age-matched weight and body mass index by gender in the pediatric population is developed by using a polynomial function and a constant coefficient to describe the interindividual variability in weight. A polynomial of up to fifth order sufficiently described the pediatric data from the Center for Disease Control (CDC) and the World Health Organization (WHO). The coefficients of variation to describe the variability were within 17%. The percentages of the CDC simulated weights for pediatrics between 0 and 5 years that fell outside the WHO 90% and 95% confidence boundaries were well within the expected percentage values, indicating that the CDC dataset can be used to substitute for the WHO dataset for the purpose of pediatric drug development. To illustrate the utility of this empirical function, the CDC-based age-matched weights were simulated and were used in the prediction of the concentration-time profiles of tenofovir in children based on a population pharmacokinetic model whose parameters were allometrically scaled. We have shown that the resulting 95% prediction interval of tenofovir in newborn to 5 years of age was almost identical whether the weights were simulated based on WHO or CDC dataset. The approach is simple and is broadly applicable in adjusting for pediatric dosages using allometry.
引用
收藏
页码:1372 / 1379
页数:8
相关论文
共 22 条
  • [1] Population Pharmacokinetics of Tenofovir in HIV-1-Infected Pediatric Patients
    Bouazza, Naim
    Urien, Saik
    Hirt, Deborah
    Frange, Pierre
    Rey, Elisabeth
    Benaboud, Sihem
    Foissac, Frantz
    Blanche, Stephane
    Treluyer, Jean-Marc
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 58 (03) : 283 - 288
  • [2] INTERSPECIES PHARMACOKINETIC SCALING AND THE EVOLUTIONARY-COMPARATIVE PARADIGM
    BOXENBAUM, H
    [J]. DRUG METABOLISM REVIEWS, 1984, 15 (5-6) : 1071 - 1121
  • [3] INTERSPECIES SCALING, ALLOMETRY, PHYSIOLOGICAL TIME, AND THE GROUND PLAN OF PHARMACOKINETICS
    BOXENBAUM, H
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1982, 10 (02): : 201 - 225
  • [4] What is the right dose for children?
    Cella, Massimo
    Knibbe, Catherijne
    Danhof, Meindert
    Della Pasqua, Oscar
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (04) : 597 - 603
  • [5] Population approaches in paediatrics
    Chatelut, Etienne
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2008, 22 (06) : 575 - 578
  • [6] DEVELOPMENT OF NORMALIZED CURVES FOR THE INTERNATIONAL GROWTH REFERENCE - HISTORICAL AND TECHNICAL CONSIDERATIONS
    DIBLEY, MJ
    GOLDSBY, JB
    STAEHLING, NW
    TROWBRIDGE, FL
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 1987, 46 (05) : 736 - 748
  • [7] Dosing in Children
    Holford, N.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (03) : 367 - 370
  • [8] A size standard for pharmacokinetics
    Holford, NHG
    [J]. CLINICAL PHARMACOKINETICS, 1996, 30 (05) : 329 - 332
  • [9] Hu TM, 2001, AAPS PHARMSCI, V3
  • [10] Kuczmarski RJ., 2002, VITAL HLTH STAT, V11, P1, DOI [DOI 10.1016/J.BBRC.2015.06.114, 10.1590/S1516-35982002000600018]